07:02 EDT Supernus (SUPN) to acquire Sage Therapeutics (SAGE) for $8.50 per share in cash plus CVR
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SUPN:
- Supernus expands partnership with Jay Glazer in new content series
- Supernus Pharmaceuticals Faces Patent Challenges for Qelbree
- Supernus announces Paragraph IV ANDA filings for Qelbree
- Supernus partners with Busy Philipps for new campaign
- Supernus Pharmaceuticals’ Earnings Call: Growth Amid Challenges